TEVA PHARMACEUTICAL INDUSTRIES LTD Quarterly Nonoperating Income (Expense) in USD from Q1 2010 to Q3 2024

Taxonomy & unit
us-gaap: USD
Description
The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).
Summary
Teva Pharmaceutical Industries Ltd quarterly/annual Nonoperating Income (Expense) history and growth rate from Q1 2010 to Q3 2024.
  • Teva Pharmaceutical Industries Ltd Nonoperating Income (Expense) for the quarter ending September 30, 2024 was -$272M, a 2.86% increase year-over-year.
  • Teva Pharmaceutical Industries Ltd Nonoperating Income (Expense) for the twelve months ending September 30, 2024 was -$1.01B, a 3.89% increase year-over-year.
  • Teva Pharmaceutical Industries Ltd annual Nonoperating Income (Expense) for 2023 was -$1.06B, a 9.42% decline from 2022.
  • Teva Pharmaceutical Industries Ltd annual Nonoperating Income (Expense) for 2022 was -$966M, a 8.7% increase from 2021.
  • Teva Pharmaceutical Industries Ltd annual Nonoperating Income (Expense) for 2021 was -$1.06B, a 26.9% decline from 2020.
Nonoperating Income (Expense), Trailing 12 Months (USD)
Nonoperating Income (Expense), Quarterly (USD)
Nonoperating Income (Expense), YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2024 -$1.01B -$272M +$8M +2.86% Jul 1, 2024 Sep 30, 2024 10-Q 2024-11-06
Q2 2024 -$1.02B -$241M +$27M +10.1% Apr 1, 2024 Jun 30, 2024 10-Q 2024-07-31
Q1 2024 -$1.05B -$250M +$10M +3.85% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-08
Q4 2023 -$1.06B -$249M -$4M -1.63% Oct 1, 2023 Dec 31, 2023 10-K 2024-02-12
Q3 2023 -$1.05B -$280M -$28M -11.1% Jul 1, 2023 Sep 30, 2023 10-Q 2024-11-06
Q2 2023 -$1.03B -$268M -$57M -27% Apr 1, 2023 Jun 30, 2023 10-Q 2024-07-31
Q1 2023 -$968M -$260M -$2M -0.78% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-08
Q4 2022 -$966M -$245M +$8M +3.16% Oct 1, 2022 Dec 31, 2022 10-K 2024-02-12
Q3 2022 -$974M -$252M -$11M -4.56% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-09
Q2 2022 -$963M -$211M +$63M +23% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-02
Q1 2022 -$1.03B -$258M +$32M +11% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-10
Q4 2021 -$1.06B -$253M +$17M +6.3% Oct 1, 2021 Dec 31, 2021 10-K 2024-02-12
Q3 2021 -$1.08B -$241M -$124M -106% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-03
Q2 2021 -$951M -$274M -$51M -22.9% Apr 1, 2021 Jun 30, 2021 10-Q 2022-07-27
Q1 2021 -$900M -$290M -$66M -29.5% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-03
Q4 2020 -$834M -$270M -$83M -44.4% Oct 1, 2020 Dec 31, 2020 10-K 2023-02-10
Q3 2020 -$751M -$117M +$94M +44.6% Jul 1, 2020 Sep 30, 2020 10-Q 2021-10-27
Q2 2020 -$845M -$223M -$17M -8.25% Apr 1, 2020 Jun 30, 2020 10-Q 2021-07-28
Q1 2020 -$828M -$224M -$6M -2.75% Jan 1, 2020 Mar 31, 2020 10-Q 2021-04-28
Q4 2019 -$822M -$187M +$36M +16.1% Oct 1, 2019 Dec 31, 2019 10-K 2022-02-09
Q3 2019 -$858M -$211M +$18M +7.86% Jul 1, 2019 Sep 30, 2019 10-Q 2020-11-05
Q2 2019 -$876M -$206M +$30M +12.7% Apr 1, 2019 Jun 30, 2019 10-Q 2020-08-05
Q1 2019 -$906M -$218M +$53M +19.6% Jan 1, 2019 Mar 31, 2019 10-Q 2020-05-07
Q4 2018 -$959M -$223M -$32M -16.8% Oct 1, 2018 Dec 31, 2018 10-K 2021-02-10
Q3 2018 -$927M -$229M +$30M +11.6% Jul 1, 2018 Sep 30, 2018 10-Q 2019-11-07
Q2 2018 -$957M -$236M +$2M +0.84% Apr 1, 2018 Jun 30, 2018 10-Q 2019-08-07
Q1 2018 -$959M -$271M -$64M -30.9% Jan 1, 2018 Mar 31, 2018 10-Q 2019-05-02
Q4 2017 -$895M -$191M +$586M +75.4% Oct 1, 2017 Dec 31, 2017 10-K 2020-02-21
Q3 2017 -$1.48B -$259M -$109M -72.7% Jul 1, 2017 Sep 30, 2017 10-Q 2018-11-01
Q2 2017 -$1.37B -$238M -$133M -127% Apr 1, 2017 Jun 30, 2017 10-Q 2018-08-02
Q1 2017 -$1.24B -$207M +$91M +30.5% Jan 1, 2017 Mar 31, 2017 10-Q 2018-05-03
Q4 2016 -$1.33B -$777M -$707M -1010% Oct 1, 2016 Dec 31, 2016 10-K 2018-02-12
Q3 2016 -$623M -$150M +$547M +78.5% Jul 1, 2016 Sep 30, 2016 6-K 2017-11-02
Q2 2016 -$1.17B -$105M -$64M -156% Apr 1, 2016 Jun 30, 2016 6-K 2017-08-03
Q1 2016 -$1.11B -$298M -$106M -55.2% Jan 1, 2016 Mar 31, 2016 6-K 2017-05-11
Q4 2015 -$1B -$70M $0 0% Oct 1, 2015 Dec 31, 2015 10-K 2018-02-12
Q3 2015 -$1B -$697M -$613M -730% Jul 1, 2015 Sep 30, 2015 6-K 2016-11-15
Q2 2015 -$387M -$41M +$37M +47.4% Apr 1, 2015 Jun 30, 2015 6-K 2016-08-04
Q1 2015 -$424M -$192M -$111M -137% Jan 1, 2015 Mar 31, 2015 6-K 2016-05-09
Q4 2014 -$313M -$70M -$11M -18.6% Oct 1, 2014 Dec 31, 2014 20-F 2017-02-15
Q3 2014 -$302M -$84M -$8M -10.5% Jul 1, 2014 Sep 30, 2014 6-K 2015-10-29
Q2 2014 -$294M -$78M +$11M +12.4% Apr 1, 2014 Jun 30, 2014 6-K 2015-07-30
Q1 2014 -$305M -$81M +$94M +53.7% Jan 1, 2014 Mar 31, 2014 6-K 2015-04-30
Q4 2013 -$399M -$59M +$87M +59.6% Oct 1, 2013 Dec 31, 2013 20-F 2016-02-11
Q3 2013 -$486M -$76M -$3M -4.11% Jul 1, 2013 Sep 30, 2013 6-K 2014-10-30
Q2 2013 -$483M -$89M +$8M +8.25% Apr 1, 2013 Jun 30, 2013 6-K 2014-07-31
Q1 2013 -$491M -$175M -$105M -150% Jan 1, 2013 Mar 31, 2013 6-K 2014-05-02
Q4 2012 -$386M -$146M -$78M -115% Oct 1, 2012 Dec 31, 2012 20-F 2015-02-09
Q3 2012 -$308M -$73M -$6M -8.96% Jul 1, 2012 Sep 30, 2012 6-K 2013-10-31
Q2 2012 -$302M -$97M -$117M -585% Apr 1, 2012 Jun 30, 2012 6-K 2013-08-01
Q1 2012 -$185M -$70M -$32M -84.2% Jan 1, 2012 Mar 31, 2012 6-K 2013-05-02
Q4 2011 -$153M -$68M -$21M -44.7% Oct 1, 2011 Dec 31, 2011 20-F 2014-02-10
Q3 2011 -$132M -$67M -$64M -2133% Jul 1, 2011 Sep 30, 2011 6-K 2012-11-01
Q2 2011 -$68M $20M +$168M Apr 1, 2011 Jun 30, 2011 6-K 2012-08-02
Q1 2011 -$236M -$38M -$11M -40.7% Jan 1, 2011 Mar 31, 2011 6-K 2012-05-09
Q4 2010 -$225M -$47M Oct 1, 2010 Dec 31, 2010 20-F 2013-02-12
Q3 2010 -$3M Jul 1, 2010 Sep 30, 2010 6-K 2011-11-02
Q2 2010 -$148M Apr 1, 2010 Jun 30, 2010 6-K 2011-07-28
Q1 2010 -$27M Jan 1, 2010 Mar 31, 2010 6-K 2011-05-11
* An asterisk sign (*) next to the value indicates that the value is likely invalid.